DURECT Corporation Overview
Pro stress-test →DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol, is in clinical development for alcoholic hepatitis (AH) with FDA Fast Track and Breakthrough Therapy designations, and is also being explored for metabolic dysfunction-associated steatohepatitis (MASH).
Strategic Profile
Pro stress-test →The company has a commercial pharmaceutical product, POSIMIR (bupivacaine solution), a non-opioid analgesic utilizing the SABER platform technology. As of September 2025, DURECT operates as a subsidiary of Bausch Health Americas with $12M in cash reserves and has shifted focus to advancing Larsucosterol with a Phase 3 trial estimated at $20M.
Competitive Landscape
Pro stress-test →DURECT's Larsucosterol targets epigenetic dysregulation in alcoholic hepatitis and MASH, competing in the growing liver disease therapeutic space against companies developing anti-fibrotic and metabolic therapies. The company faces competition from larger pharma and biotech firms with more substantial clinical pipelines and financial resources for Phase 3 trials.
Industry Context
DURECT Corporation operates in Biopharmaceuticals & Drug Delivery.
Key facts
Founded: 1998 · Headquarters: Cupertino, California · Revenue: $2M (2024) · Market cap: N/A